Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2003-10-28
2009-11-17
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100
Reexamination Certificate
active
07618790
ABSTRACT:
The present invention concerns a method for the in vitro diagnosis of breast cancer which consists in determining the presence of NGF in a biological sample derived from a patient suspected of suffering from breast cancer. Said method may be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in the diagnosis of relapse in the case of breast cancer.The present invention also concerns the use of an NGF binding partner or of an NGF inhibitor for preparing a medicinal product, said medicinal product being in particular useful for blocking tumor proliferation and remote dissemination in patients suffering from breast cancer.
REFERENCES:
patent: 2003/0104364 (2003-06-01), Billing-Medel et al.
patent: 2 781 802 (2001-05-01), None
patent: WO 94/06935 (1994-03-01), None
patent: WO 95/08000 (1995-03-01), None
patent: WO 97/38313 (1997-10-01), None
patent: WO 03/076942 (2003-09-01), None
Sakamoto et al, Oncol Rep, 2001 8:973-980.
Sakamoto et al., Oncol Rep, Sep.-Oct. 2001, 8:973-980.
Varilek et al., Am J Physiol. 1995, 269:G445-G452.
Picker et al., Blood, 1995, 86:1408-1419.
Tockman et al, Cancer Res., 1992, 52:2711s-2718s).
Slamon et al., Science vol. 235, Jan. 1987, pp. 177-182.
Pica et al, AIDS, 1998, 12:2025-2029.
Bigazzi et al, Clin Endocrinol, 1977, 6:105-112.
Basuyau et al., “Standards, Options and Recommendations (SOR) for Tumor Markers in Breast Cancer,”Bull Cancer2000, No. 87, pp. 723-737 {2000}.
Springer, “Immunoreactive T and Tn Epitopes in Cancer Diagnosis, Prognosis, and Immunotherapy,”J. Mol. Med., No. 75, pp. 594-602 {1997}.
Gnjactic et al., “Accumulation of the p53 Protein Allows Recognition by Human CTL of a Wild-Type p53 Epitope Presented by Breast Carcinomas and Meloanomas,”Journal of Immunology., No. 160, pp. 328-333 {1998}.
Disis et al., “HER-2
eu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer,”Adv Cancer Res., No. 71, pp. 343-371 {1997}.
Jager et al., “Cancer-testis Antigens and ING1 Tumor Suppressor Gene Product are Breast Cancer Antigens: Characterization of Tissue-Specific ING1 Transcripts and a Homologue Gene,”Cancer Research, No. 59; pp. 6197-6204 {1999}.
Jager et al., “Identification of a Tissue-Specific Putative Transcription Factor in Breast Tissue by Serological Screening of a Breast Cancer Library,”Cancer Research, No. 61, pp. 2055-2061 {2001}.
Scanlan et al., “Challenges to the Development of Antigen-Specific Breast Cancer Vaccines,”Breast Cancer Research, No. 3, pp. 95-98 {2001}.
Descamps et al., “Nerve Growth Factor is Mitogenic for Cancerous But Not Normal Human Breast Epithelial Cells,”The Journal of Biological Chemistry, vol. 273, No. 27, pp. 16659-16662 {Jul. 3, 1998}.
Descamps et al., “Nerve Growth Factor Stimulates Proliferation and Survival of Human Breast Cancer Cells Through Two Distinct Signaling Pathways,”The Journal of Biological Chemistry, vol. 276, No. 21, pp. 17864-17870 {May 25, 2001}.
Levi-Montalcini et al., “The Nerve Growth Factor 35 Years Later,”Science, vol. 237, pp. 1154-1162 {1987}.
Torcia et al., “Nerve Growth Factor is an Autocrine Survival Factor for Memory B Lymphocytes,”Cell, vol. 85, pp. 345-356 {May 3, 1996}.
Descamps et al., “Expression of Nerve Growth Factor Receptors and Their Prognostic Value in Human Breast Cancer,”Cancer Research, No. 61, pp. 4337-4340 {Jun. 1, 2001}.
Bonini et al., “Circulating Nerve Growth Factor Levels are Increased in Humans with Allergic Diseases and Asthma,”Proc. Natl. Acad. Sci. USA, vol. 93, pp. 10955-10960 {Oct. 1996}.
Chevalier et al., “Biotin and Digoxigenin as Labels for Light and Electron Microscopy in Situ Hybridization Probes: Where Do We Stand?”The Journal of Histochemistry&Cytochemistry, vol. 45, No. 4, pp. 481-491 {1997}.
Patterson, “Mass Spectrometry and Proteomics,”Physiological Genomics2, pp. 59-65 {2000}.
Metezeau et al.,La Cytometrie En Flux, vol. I, Medsi/McGraw-Hill Publications, pp. 21-74 {before Oct. 2003}.
Intracellular Flow Cytometry,:Applied Reagents and Techniques, pp. 1-21, BD Pharmingen {Oct. 2000}.
Hondermarck et al., “Early Changes in Protein Synthesis Induced by Basis Fibroblast Growth Factor, Nerve Growth Factor, and Epidermal Growth Factor in PC12 Pheochromocytoma Cells,”Proc. Natl. Acad. Sci. USA, vol. 91, pp. 9377-9381 {Sep. 1994}.
Hattori et al., “Tumor Necrosis Factor Stimulates the Synthesis and Secretion of Biologically Active Nerve Growth Factor in Non-neuronal Cells,”The Journal of Biological Chemistry, vol. 268, No. 4, pp. 2577-2582 {Feb. 5, 1993}.
Kumar et al., “The first Analogues of LNA (Locked Nucleic Acids): Phosphorothioate-LNA and 2′-Thio-LNA,”Bioorganic&Medicinal Chemistry Letters, vol. 8, Issue 16, pp. 2219-2222 {Aug. 18, 1998}.
Egholm et al., “Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone,”J. Am. Chem. Soc., No. 114, pp. 1895-1897 {1992}.
Tapley et al., “K252a is a Selective Inhibitor of the Tyrosine Protein Kinase Activity of thetrkFamily of Oncogenes and Neurotrophin Receptors,”Oncogene, No. 7, pp. 371-381 {1992}.
Dykxhoorn et al., “Killing the Messenger: Short RNAs that Silence Gene Expression,”Nature Review, vol. 4, pp. 457-467 {Jun. 2003}.
Maleck et al., “Methods in Molecular Biology”, No. 28, Ch. 36, Ed P.G. Issac, Humana Press, Inc., Totowa, NJ {1994}.
Cramer et al., “Nerve Growth Factor in Medullary Carcinoma of the Thyroid”, Human Pathology, vol. 10, No. 6, pp. 731-736, Nov. 1979.
Gorctzki, M.D., R. A., “Nerve Growth Factor (NGF) Sensitizes Human Medullary Thyroid Carcinoma (hMTC) Cells for Cytostatic Therapy In Vitro”, Surgery, pp. 1035-1042, Dec. 1987.
Moley et al., “Oncogene and Growth Factor Expression in MEN 2 and Related Tumors”, Henry Ford Hosp. Med. Journal, vol. 40, No. 3 & 4, pp. 284-288, 1992.
Pica et al., “Autocrine Nerve Growth Factor is Essential for Cell Survival and Viral Maturation in HHV-8-Infected Primary Effusion Lymphoma Cells”, Blood, vol. 95, No. 9, pp. 2905-2912, May 1, 2000.
Van Der Laan et al., “Expression of Growth Factors and Growth Factor Receptors in Normal and Tumorous Human Thyroid Tissues”, Thyroid, vol. 5, No. 1, pp. 67-73, 1995.
Adriaenssens Eric
Choquet-Kastylevsky Genevieve
Dolle Laurent
El-Yazidi Belkoura Ikram
Hondermarck Hubert
Biomerieux
Halvorson Mark
Oliff & Berridg,e PLC
Universite des Sciences et Technologies de Lille
Yu Misook
LandOfFree
Method for NGF assay for in vitro diagnosis of breast cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for NGF assay for in vitro diagnosis of breast cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for NGF assay for in vitro diagnosis of breast cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4055106